💊 Orforglipron: A new era in obesity treatment?
In the ATTAIN-1 trial, this oral, nonpeptide GLP-1 receptor agonist delivered up to 11.2% weight loss over 72 weeks—with significant drops in waist circumference, triglycerides, and blood pressure 📉🌡️
🔥 Nearly 1 in 5 patients lost ≥20% body weight
💡 A promising alternative to injectable therapies
Accessible. Effective. Oral.
👉 A game-changer for global obesity care?
#Obesity #GLP1 #Orforglipron #WeightLoss #CardiometabolicHealth #NEJM #Innovation #ClinicalTrials #Endocrinology #PublicHealth #Pharmacotherapy
